An evaluation of utility measurement in Crohn's disease

Inflammatory Bowel Diseases

Volumn 3, Issue 4, 1997, Pages 265-276

  Gregor, James C ^a   McDonald, John W D ^a   Klar, Neil ^a   Wall, Ronald ^a   Atkinson, Kenneth ^a   Lamba, Binu ^a   Feagan, Brian G ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Crohn's disease; Health related quality of life; Inflammatory bowel disease; Standard Gamble; Time Trade Off; Utility measurement

Indexed keywords

EID: 0001051932     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780030405     Document Type: Review

References (41)

1. Love JR, Irvine EJ, Fedorak RN. Quality of life in IBD. J Clin Gastroenterol 1992;14:15-9.
2. Drossman DA, Patrick DL, Mitchell CM, Murp EA, Zagomi EA, Appelbaum MI. Health related quality of life in IBD: functional status and patient worries and concerns. Dig Dis Sci 1989;34: 1379-86.
3. Hay JW, Hay AR. Inflammatory bowel disease: Cost-of-illness. J Clin Gastroenterol 1992;14,4:318-27.
4. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
5. Spilker B ed. Quality of life assessments and pharmacoeconomics in clinical trials, 2nd ed. New York: Raven Press, 1996.
6. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with IBD. J Clin Gastroenterol 1988;10:306-10.
7. Guyatt GH, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in IBD. Gastroenterology 1989;96:804-10.
8. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
9. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846-51.
10. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
11. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
12. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987;40:593-600.
13. Richardson J. Cost utility analyses: what should be measured? Soc Sci Med 1994;39:7-21.
14. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford (Oxfordshire): New York: Oxford University Press, 1987.
15. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296: 716-21.
16. Detsky AS, McLaughlin JR, Abrams HB, et al. A cost-utility analysis of the home parenteral nutrition program at Toronto General Hospital: 1970-1982. JPEN 1986;10:49-57.
17. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-5.
18. McCabe RP, Woody S, van Denter S, et al. A multicentre trial of cA2 anti-TNF chimeric monoclonal antibodies in patients with active Crohn's disease. Gastroenterol 1996;110(suppl 4):A962.
19. McLeod RS, Churchill DN, Lock AM, Vanderburgh S, Cohen Z. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology 1991;101,5:1307-13.
20. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
21. Hollingshead AB. Two-factor index of social position. New York: Psychological Corp., 1957.
22. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterol 1976;70:439-44.
23. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978;31:697-704.
24. Froberg DG, Kane RL. Methodology for measuring health-state preferences - II: scaling methods. J Clin Epidemiol 1989;42:459-71.
25. Churchill DN, Torrance GW, Taylor DW, et al. Measurement of quality of life in end-stage renal disease: the Time Trade Off approach. Clin Invest Med 1987;10:14-20.
26. Von Neumann J, Morgenstern O. Theory of games and economic behaviour. New York: John Wiley: 1953.
27. Bakker C, Rutten van Molken M, Hidding A, van Doorslaer E, Bennett K, van der Linden S. Patient utilities in ankylosing spondylitis and the association with other outcome measures. J Rheumatol 1994;21,7:1298-304.
28. Bartko JJ. Measures of agreement: a single procedure. Stat Med 1994;13:737-45.
29. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7.
30. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987;40:171-8.
31. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Controlled Clin Trials 1991;12:142-58S.
32. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 1981;2:93-113.
33. Donner A, Eliasziw M. Sample size requirements for reliability studies. Stat Med 1987;6:441-8.
34. Kramer MS, Feinstein AR. The biostatistics of concordance. Clin Pharmacol Ther 1981;29,1:111-22.
35. Cohen J. Quantitative methods in psychology: a power primer. Psychol Bull 1992;112:155-9.
36. Tosteson ANA, Kneeland TS, Nease RF, Sumner W, Minshall M, Draper M. Feasibility of automated utility assessment in phase III clinical trials: U-titer and a raloxifene osteoporosis prevention trial. Proceedings of the 17th Annual Meeting of the Society for Medical Decision Making, Tempe, AZ, October 1995.
37. Nease RF, Kneeland T, O'Connor GT, et al. Variations in patient utilities for outcomes of the management of chronic stable angina. JAMA 1995;273:1185-90.
38. Wakker P, Stiggelbout A. Explaining distortions in utility elicitation through the rank-dependent model for risky choices. Med Decis Making 1995;15:180-6.
39. Tsevat J, Cook EF, Green ML, et al. Health values of the seriously ill: SUPPORT investigators. Ann Intern Med 1995;122:514-20.
40. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
41. Drummond MF, Jefferson TO on behalf of the BMJ Economic Evaluation Working Party: guidelines for the authors and peer reviewers of economic submissions to the BMJ. Br Med J 1996; 313:275-83.